Osny

Researchers are investigating the use of endoscopic surgery as a less invasive alternative to traditional lumbar spine fusion for patients with spinal stenosis and spondylolisthesis. This approach aims to decompress the lumbar spine while preserving its natural function and stability, potentially reducing the need for spinal fusion. The study explores whether endoscopic techniques can lower the rate of more invasive surgical interventions in this population. The study focuses on patients who require spinal decompression surgery and are considered for endoscopic procedures. It observes outcomes related to these minimally destructive surgical methods without introducing experimental drugs or devices. The main goal is to evaluate the rate of surgical reintervention within one year after the initial endoscopic surgery. Participants will be monitored over time to assess if further surgical procedures are needed. Researchers will review medical imaging and clinical data to understand the effectiveness of endoscopic decompression in avoiding fusion surgery. The study involves adults 18 years and older and tracks outcomes related to surgical reintervention during the follow-up period, with participation potentially lasting up to several years.

This research investigates GLSI-100 immunotherapy in people with HER2neu positive breast cancer who are at high risk for their cancer returning. It focuses on participants who have completed both neoadjuvant and postoperative adjuvant standard treatments. The study is Phase 3, randomized, double-blinded, and placebo-controlled, involving subjects who are HLA-A*02 positive as well as an open-label group of non-HLA-A*02 positive subjects. The goal is to evaluate the treatments impact on invasive breast cancer-free survival over a median follow-up of 4 years. Participants receive 6 primary immunization injections of GLSI-100 or placebo intradermally once a month for the first 6 months, followed by 5 booster injections spaced 6 months apart, totaling 11 injections over 3 years. There are three groups one receiving placebo 0.9% normal saline, one receiving GLSI-100 immunotherapy in HLA-A*02 positive subjects, and an open-label arm for non-HLA-A*02 positive subjects receiving GLSI-100 under the same schedule. During the study, participants undergo regular monitoring and assessments including invasive disease-free survival, distant disease-free survival, overall survival, and quality of life questionnaires at baseline and up to 36 months. Researchers track safety and treatment effects over a median 4-year follow-up. The study continues until December 2031, aiming to provide comprehensive data on long-term outcomes and quality of life for participants receiving these treatments.

Squamous cell carcinoma of the anus is a rare but increasingly common cancer, often linked to human papillomavirus HPV. For early-stage tumors, combined radiotherapy and chemotherapy with 5FU and mitomycin-C provide good outcomes, but advanced tumors have a poor prognosis with a high relapse rate. Researchers are studying a new approach combining induction chemotherapy with docetaxel, cisplatin, and 5FU mDCF followed by standard chemoradiotherapy to improve treatment results for locally advanced anal cancer T3-4 or N1. This is a randomized phase 3 trial comparing this new strategy to the current standard treatment. The study includes two groups one receives the usual chemoradiotherapy, which involves 33 radiotherapy sessions over 6.5 weeks combined with mitomycin-C and capecitabine chemotherapy taken on radiotherapy days. The other group starts with 4 cycles of mDCF chemotherapy given every two weeks before receiving the same chemoradiotherapy as the control group. Radiotherapy uses intensity-modulated external irradiation with a targeted boost to the tumor and involved lymph nodes. Participants will be followed after treatment with check-ups at 8 weeks, then every 4 months for two years, and every 6 months in the third year. Follow-up includes clinical exams and imaging scans CT and MRI. The main measure of success is disease-related event-free survival two years after treatment. Other outcomes include overall survival, colostomy-free survival, treatment side effects, tumor response, and quality of life. The total study duration for each participant may extend over several years including this follow-up period.

This research aims to observe patients in France with HER2-negative early breast cancer who are treated with olaparib, a medication chosen by their doctors. The study focuses on understanding how often patients complete the full course of olaparib treatment and gathers information on related genetic factors and medical history. It is a national, multicenter, prospective observational study without experimental treatment assignment. Participants in this study receive adjuvant olaparib treatment as part of their usual care under their physicians discretion. The study does not assign treatments but follows patients who start olaparib, tracking their treatment progress for up to 18 months after inclusion. There are no additional interventions or placebo groups. Throughout the study, researchers collect data on treatment completion rates, types of BRCA mutations, variant types, medical history, and the time until olaparib treatment stops. Participation involves observational follow-up, with no extra treatment visits beyond routine care. The overall participation lasts 18 months after a patients enrollment, focusing on real-world treatment experiences and outcomes.

This trial investigates whether postmenopausal women aged 60 and older with early-stage, low-risk hormone receptor-positive breast cancer can safely avoid hormone therapy after surgery without increasing the risk of cancer relapse. The study focuses on women with small, low-grade tumors classified as Luminal A subtype, which generally have an excellent prognosis and low recurrence rates. Researchers aim to better understand the balance of treatment benefits and side effects, especially considering the long-term burden of hormone therapy on quality of life. Participants will not receive the standard hormone therapy such as tamoxifen or aromatase inhibitors during the study. All participants will have undergone surgery and possibly radiation therapy prior to enrollment. This study enrolls participants for two years and compares their outcomes to historical data from patients who received hormone therapy, assessing cancer recurrence and health outcomes over time. During the trial, participants will be monitored for up to five years after the last enrollment to track relapse-free survival, incidence of new breast cancer events, distant disease-free survival, overall survival, and quality of life. Evaluations will include questionnaires on quality of life, anxiety, and depression, as well as monitoring for bone health, cardiovascular events, and other treatment-related conditions. The study aims to provide evidence for more personalized treatment approaches and to improve shared decision-making for women with low-risk breast cancer.

The trial investigates whether adding a digital telemonitoring platform called CUREETY TECHCARE to the usual care can improve outcomes for patients with metastatic triple-negative breast cancer who have not received prior treatment and are starting their first systemic therapy. It aims to understand if telemonitoring can enhance patient quality of life, reduce hospitalization rates, and improve overall survival compared to standard care alone. Participants in the telemonitoring group will use the Cureety platform weekly to report symptoms. The platform analyzes these symptoms and classifies the patients condition into risk categories, which guide tailored advice and alerts for medical staff. The medical team monitors patients daily via the platform and adjusts care as needed. The comparison group receives standard care without telemonitoring. During the study, patients complete quality of life questionnaires at baseline and regular intervals up to 24 months. Researchers will track time to quality of life deterioration, hospitalization-free survival, and overall survival as primary outcomes. Secondary outcomes include treatment toxicity, treatment failure, clinical deterioration, adverse events, treatment compliance, satisfaction with telemonitoring, and socio-economic impacts. The study involves ongoing monitoring, data collection, and patient questionnaires over two years to assess the benefits and effects of telemonitoring.